Benutzerspezifische Werkzeuge

Developing a Core Outcome Set for future clinical trials for the management of Vitiligo

Developing a Core Outcome Set for future clinical trials for the management of Vitiligo

Vitiligo is the most common depigmentation disorder, which affects around 1% of the population worldwide. Currently, no cure or firm clinical recommendations exist for the treatment of this disorder. One of the main issues identified by the Cochrane systematic review [1] was the heterogeneity of outcomes and outcome measures used in randomised controlled trials for vitiligo.

Dr Viktoria Eleftheriadou conducted a systematic review on outcomes in vitiligo trials 2 , as part of her doctoral degree (2012).  This review showed that 25 different outcomes had been measured in 54 randomised controlled trials. Since then, core outcomes set was identified as a priority issue on the agenda of Vitiligo Global Issues Consensus Group (VGICG). Dr Eleftheriadou is a post-doctoral researcher with interest in vitiligo and a resident Physician. After completing her PhD at the Centre of Evidence Based Dermatology, University of Nottingham, she works on the development of core outcomes set for vitiligo trials amongst other vitiligo projects.

Pr Khaled Ezzedine has a long clinical experience with vitiligo and sees over 1000 patients per year with vitiligo. He has a PhD in Epidemiology and is part of the Vitiligo Global Issues Consensus Group and the VETF. He recently published the Vitiligo seminar in the Lancet 3 .

Recently an international e-Delphi consensus on core outcomes set for vitiligo, led by Dr Viktoria Eleftheriadou and Prof. Khaled Ezzedine, was completed 4 (2015).  A hundred and one participant from 25 countries worldwide took part including patients, clinicians, representatives of regulatory authorities and journal editors. Three outcomes were identified as essential: repigmentation, cessation of spread and side effects.

Currently, international vitiligo research society and the VGICG are working on a unified scale to measure the above mentioned outcomes. In particular, a face to face workshop is planned to be held in September 2016, in Rome.

Contact: Khaled EZZEDINE  ‎


1 Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, Ezzedine K. Interventions for vitiligo. Cochrane Data System Rev 2015, Issue 2. Art. No.: CD003263.

2 Eleftheriadou V, Thomas K, Whitton M et al. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey amongst patients and clinicians on outcomes in vitiligo trials. Br. J. Dermatol 2012; 167, 804–814.

3 Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015; 386:74-84.

4 Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, Silva de Castro CC, Pandya A, Goh BK, Lan CC, Oiso N, Al Issa A, Esmat S, Le Poole C, Lee AY, Parsad D, Taieb A, Picardo M, Ezzedine K. Vitiligo Global Issues Consensus Group. Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res 2015; 28, 363-9.